Hyperopic LASIK combined with higher-fluence topography-customised application of CXL irradiation

Session Details

Session Title: Presented Poster Session: Refractive

Venue: Poster Village: Pod 3

First Author: : A.Kanellopoulos GREECE

Co Author(s): :                           

Abstract Details

Purpose:

To report a novel application of topographically-customized collagen crosslinking aiming to achieve refractive and keratometric stability following hyperopic LASIK.


Setting:

LaserVision.gr Clinical and Research Eye Institute, Athens, Greece

Methods:

Topography-guided treatment employed (a) surgery planning by Placido-topography (Vario, Alcon, Ft. Worth, TX) (b) femto-second-laser assisted corneal flap 140-μm deep, 9.5-mm diameter (FS200, Alcon) (c) excimer-laser ablation centered on the 1st Purkinje-reflection (EX500, Alcon). Following ablation, with the flap folded onto itself, protected with a dry Wexel sponge, 0.10% saline- diluted riboflavin was placed on the stromal bed for 60-seconds. Then a peripheral annular-shaped topographically customizable design was employed for high-fluence UV-A irradiation (KXL II, Avedro, Waltham, MA). Visual acuity, cornea clarity, keratometry, topography, and pachymetry, including corneal epithelial pachymetry, as well as endothelial cell counts were evaluated.


Results:

42 eyes were available for follow-up up to 2-years. Uncorrected distance visual acuity improved from 5.5/10 to 9.2/10. At 24 (8–37) months, 75.5% of the eyes were in the ±0.50 D range and 94.4% were in the ±1.00 D range of the refractive goal. Postoperatively, the mean sphere value was −0.39 ± 0.3 and the cylinder value was −0.35 ± 0.25. Topographic evidence showed that ablation was made in the visual axis and not in the center of the cornea, thus correlating with the angle kappa. No significant complications were encountered.


Conclusions:

We introduce here in the novel application of a topographically customizable collagen crosslinking application to achieve refractive and keratometric stability following hyperopic LASIK.

Financial Disclosure:

None